Skip to main content
. Author manuscript; available in PMC: 2016 Aug 1.
Published in final edited form as: J Allergy Clin Immunol. 2015 Mar 29;136(2):441–453. doi: 10.1016/j.jaci.2015.02.014

Fig 7.

Fig 7

UFP activates AhR to induce Jag1 expression. (A) Fold change of Jag1 transcripts in BMDCs treated with PBS, Af-UFP, UFP and N-UFP (10 µg/ml). (B and C) Flow cytometric analysis of Jag1 expression (B) and Jag1 mRNA levels (C) in BMDCs treated with DMSO (sham), UFP, AhR agonist 6-FICZ, in the presence or absence of AhR antagonist CH223191. (D–F) Flow cytometric analysis of Jag1 expression (D) and Jag1 (E) and Ahr (F) mRNA levels in WT or CD11c-Cre+AhRΔ/Δ BMDCs. (G) Schematic representation of candidate AhR bindings sites in the proximal Jag1 promoter. (H–J) ChIP analysis of AhR binding to candidate response elements in the Jag1 promoter in BMDCs treated with the indicated reagents. (K) Luciferase activity in BMDCs transfected with luciferase reporters driven by individual candidate Jag1 AhR response elements then treated with vehicle (DMSO), UFP or 6-FICZ. Results are representative of 3 independent experiments. N=3–7/group. p***<0.001, ****<0.0001 by one and two way ANOVA with Bonferroni post test analysis.